U.S. markets open in 2 hours 43 minutes

Incyte Corporation (INCY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
65.56+1.34 (+2.09%)
At close: 4:00PM EDT
65.56 0.00 (0.00%)
Pre-Market: 06:27AM EDT

Incyte Corporation

1801 Augustine Cut-Off
Wilmington, DE 19803
United States
302 498 6700

Full Time Employees1,773

Key Executives

NameTitlePayExercisedYear Born
Mr. Herve HoppenotChairman, Pres & CEO2.55M8.07M1960
Ms. Christiana StamoulisExec. VP & CFO989.39kN/A1971
Dr. Vijay K. Iyengar M.D.Exec. VP of Global Strategy & Corp. Devel.945.9k252.81k1973
Dr. Barry P. Flannelly M.B.A., Pharm.D., MBAExec. VP & GM of North America833.63k1.19M1958
Dr. Steven H. SteinExec. VP & Chief Medical Officer967.8k1.3M1967
Mr. Michael James MorrisseyExec. VP & Head of Global Technical OperationsN/AN/A1964
Dr. Dashyant Dhanak Ph.D.Exec. VP & Chief Scientific OfficerN/AN/A1961
Ms. Christine ChiouHead of Investor RelationsN/AN/AN/A
Ms. Maria E. PasqualeExec. VP & Gen. CounselN/AN/A1966
Ms. Pamela M. MurphyVP of Investor Relations & Corp. CommunicationsN/AN/A1951
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Corporate Governance

Incyte Corporation’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.